Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current and Emerging Therapies for Duchenne Muscular Dystrophy
Megan Crone, Jean K. Mah
Current Treatment Options in Neurology (2018) Vol. 20, Iss. 8
Closed Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Muscle cell‐derived cytokines in skeletal muscle regeneration
Rachel J. Waldemer, Dong‐Wook Kim, Jie Chen
FEBS Journal (2022) Vol. 289, Iss. 21, pp. 6463-6483
Open Access | Times Cited: 42
Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy
Angela Lek, Tracy Zhang, Keryn G. Woodman, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 536
Open Access | Times Cited: 61
Myogenesis modelled by human pluripotent stem cells: a multi‐omic study of Duchenne myopathy early onset
Virginie Mournetas, Emmanuelle Massouridès, Jean‐Baptiste Dupont, et al.
Journal of Cachexia Sarcopenia and Muscle (2021) Vol. 12, Iss. 1, pp. 209-232
Open Access | Times Cited: 48
Neuroprotection through G-CSF: recent advances and future viewpoints
Vikrant Rahi, Sumit Jamwal, Puneet Kumar
Pharmacological Reports (2021) Vol. 73, Iss. 2, pp. 372-385
Closed Access | Times Cited: 37
In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse
Leonela Amoasii, Hui Li, Yu Zhang, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 36
Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers
Neil Datta, Partha S. Ghosh
Current Neurology and Neuroscience Reports (2020) Vol. 20, Iss. 6
Closed Access | Times Cited: 36
Effects of chronic treatment with gold nanoparticles on inflammatory responses and oxidative stress in Mdx mice
Daniela Pacheco dos Santos Haupenthal, Jonathann Corrêa Possato, Rubya Pereira Zaccaron, et al.
Journal of drug targeting (2019) Vol. 28, Iss. 1, pp. 46-54
Closed Access | Times Cited: 28
A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
Gist H. Farr, Melanie S. Morris, Arianna Gómez, et al.
Skeletal Muscle (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 24
Two years of newborn screening for Duchenne muscular dystrophy as a part of the statewide Early Check research program in North Carolina
Katerina S. Kucera, Beth Lincoln Boyea, Brooke Migliore, et al.
Genetics in Medicine (2023) Vol. 26, Iss. 1, pp. 101009-101009
Open Access | Times Cited: 9
Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy
Lakshmi Krishna, Akila Prashant, Yogish H. Kumar, et al.
Neurology International (2024) Vol. 16, Iss. 4, pp. 731-760
Open Access | Times Cited: 3
Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model
Lucía Echevarría, Philippine Aupy, Karima Relizani, et al.
Nucleic Acid Therapeutics (2019) Vol. 29, Iss. 3, pp. 148-160
Closed Access | Times Cited: 25
TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy
Dengqiu Xu, Sijia Li, Lu Wang, et al.
Journal of Cachexia Sarcopenia and Muscle (2020) Vol. 12, Iss. 1, pp. 192-208
Open Access | Times Cited: 22
Mimicking sarcolemmal damage in vitro: a contractile 3D model of skeletal muscle for drug testing in Duchenne muscular dystrophy
A. Tejedera-Villafranca, Marisol Montolio, Javier Ramón‐Azcón, et al.
Biofabrication (2023) Vol. 15, Iss. 4, pp. 045024-045024
Open Access | Times Cited: 8
Mutation pattern in 606 Duchenne muscular dystrophy children with a comparison between familial and non-familial forms: a study in an Indian large single-center cohort
Kiran Polavarapu, Veeramani Preethish‐Kumar, Sekar Deepha, et al.
Journal of Neurology (2019) Vol. 266, Iss. 9, pp. 2177-2185
Closed Access | Times Cited: 22
Polymeric nanoparticles functionalized with muscle-homing peptides for targeted delivery of phosphatase and tensin homolog inhibitor to skeletal muscle
Di Huang, Feng Yue, Jiamin Qiu, et al.
Acta Biomaterialia (2020) Vol. 118, pp. 196-206
Open Access | Times Cited: 19
Modeling neuromuscular diseases in zebrafish
Jaskaran Singh, Shunmoogum A. Patten
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 11
In vivo cerebellar circuit function is disrupted in an mdx mouse model of Duchenne muscular dystrophy
Trace L. Stay, Lauren N. Miterko, Marife Arancillo, et al.
Disease Models & Mechanisms (2019) Vol. 13, Iss. 2
Open Access | Times Cited: 16
The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice
Yasunari Matsuzaka, Jun Tanihata, Yoshiko Ooshima, et al.
BMC Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 16
Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway
Dengqiu Xu, Lei Zhao, Sijia Li, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 7, pp. 1080-1089
Open Access | Times Cited: 14
Duchenne muscular dystrophy
Atchayaram Nalini
(2020)
Open Access | Times Cited: 12
Systemically Administered Homing Peptide Targets Dystrophic Lesions and Delivers Transforming Growth Factor-β (TGFβ) Inhibitor to Attenuate Murine Muscular Dystrophy Pathology
Aqsa Iqbal, Ulrike May, Stuart Prince, et al.
Pharmaceutics (2021) Vol. 13, Iss. 9, pp. 1506-1506
Open Access | Times Cited: 11
Comprehensive Molecular Analysis of DMD Gene Increases the Diagnostic Value of Dystrophinopathies: A Pilot Study in a Southern Italy Cohort of Patients
Fatima Domenica Elisa De Palma, Marcella Nunziato, Valeria D’Argenio, et al.
Diagnostics (2021) Vol. 11, Iss. 10, pp. 1910-1910
Open Access | Times Cited: 11
Soluble Factors Associated with Denervation-induced Skeletal Muscle Atrophy
Marianny Portal Rodríguez, Claudio Cabello‐Verrugio
Current Protein and Peptide Science (2023) Vol. 25, Iss. 3, pp. 189-199
Closed Access | Times Cited: 4
Unmet Therapeutic Needs of Non-Ambulatory Patients with Duchenne Muscular Dystrophy: A Mixed-Method Analysis
Anne L. R. Schuster, Norah L. Crossnohere, Ryan Fischer, et al.
Therapeutic Innovation & Regulatory Science (2022) Vol. 56, Iss. 4, pp. 572-586
Open Access | Times Cited: 6
Diagnostic Pathway to Nonsense Mutation Dystrophinopathy: A Tertiary-Center, Retrospective Experience
Didem Ardıçlı, Göknur Haliloğlu, Mehmet Alikaşifoğlu, et al.
Neuropediatrics (2018) Vol. 50, Iss. 01, pp. 041-045
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top